Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Aimovig TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: erenumab
Brand name
(ARTG)
: AIMOVIG erenumab (rch) 70 mg/mL solution for injection in pre-filled penDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Aimovig is indicated for prophylaxis of migraine in adults
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- sterile, preservative-free solution, clear to opalescent; colourless to yellowish solution, practically free from particles.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pre-filled pen pack
- 2 pre-filled pens pack
- 6 (multipack 3x2) pre-filled pens pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient erenumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.